A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients

BMC Cardiovascular Disorders

Ognjenka Djurdjev³  Mila Tang²  Karin Humphries⁴  Mhairi K Sigrist⁵  Prathibha De Zoysa³  Taylor Perry³  Adeera Levin¹ 

[1] University of British Columbia, 1081 Burrard Street, Room 6010A, Vancouver, BC V6Z 1Y6, Canada;BC Provincial Renal Agency (BCPRA), 700-1380 Burrard Street, Vancouver, BC V6Z 2H3, Canada;Providence Health Care Research Institute (PHCRI), St. Paul’s Hospital, 1081 Burrard Street, Room 302, Vancouver, BC V6Z 1Y6, Canada;Providence Health Care (PHC), Division of Cardiology, Vancouver, BC V6Z 1Y6, Canada;Division of Nephrology Research - University of British Columbia/Providence Health Care, Vancouver, BC V6Z 1Y6, Canada

关键词: Randomized protocol study;    PWV;    Vascular stiffness;    Vitamin D;    Chronic kidney disease;   

Others  :  1088710
DOI  :  10.1186/1471-2261-14-156

 received in 2014-03-06, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Vitamin D deficiency is associated with cardiovascular (CV) risk in multiple populations, including those with chronic kidney disease (CKD). The active form of the hormone (1,25 OH₂D₃₎ binds to receptors in multiple organs. CKD patients are deficient in both 25 Vitamin D and 1,25 OH₂D₃. Clinical trial data demonstrating the benefits of vitamin D formulations are limited, and fail to show significant benefits on CV outcomes, and have compared different compounds, in various populations, and focused on a variety of outcomes. A understanding of the mechanism by which different vitamin D compounds confer CV protection in CKD is important for the design of future studies.

Methods/Design

This 3 arm randomized prospective double-blinded placebo-controlled study examining the impact of calcitriol (1,25 OH₂D₃) and 25-hydroxyvitamin D3 supplementation compared to placebo on vascular stiffness, as measured by pulse wave velocity (PWV). Patients are enrolled from 2 tertiary care institutions if they meet inclusion criteria (stable estimated glomerular filtration rate (eGFR) between 15-45ml/min, <±5ml/min change in previous 6 months), on stable doses of renin-angiotensin aldosterone system blockade. For those already receiving vitamin D therapies, a 3 month washout period before randomization is mandatory. Treatment duration is 6 months; medications are given thrice weekly in fixed doses. The primary outcome measure is Vascular stiffness, measured non-invasively by pulse wave velocity (PWV). Other measurements include BP, kidney function and serial blood levels of biomarkers. The primary analysis will compare any vitamin D therapy versus placebo for the primary outcome defined as the change of PWV from baseline to 6 months. Analysis of covariance will be used to detect differences between vitamin D preparations in the magnitude of reduction in PWV.

Discussion

This study is novel in that we are using a robust study design in CKD patients (not on dialysis) comparing placebo to different forms of vitamin D supplementation in fixed doses, irrespective of baseline values. We hope to demonstrate the biological mechanistic effect of vitamin D supplementation on vascular function in order for this information to be used in designing larger randomized controlled trials.

Trial registration

Current Controlled Trials NCT01247311. Date of Registration: November 12, 2010.

【 授权许可】

   
2014 Levin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305. Write to the Help Desk NCBI NLM NIH Department of Health & Human Services Privacy Statement Freedom of Information Act Disclaimer
• [2]Levin A, Le Barbier M, Er L, Andress D, Sigrist MK, Djurdjev O: Incident isolated 1,25(OH)(2)D(3) deficiency is more common than 25(OH)D deficiency in CKD. J Nephrol 2012, 25(2):204-210.
• [3]Jun M, Lv J, Perkovic V, Jardine MJ: Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis 2011, 2(4):265-278.
• [4]Johal M, Levin A: Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(9):1508-1514.
• [5]Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
• [6]Autier P, Gandini S: Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167(16):1730-1737.
• [7]Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007, 104(43):16810-16815.
• [8]Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE: The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012, 33(1):159-171.
• [9]de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376(9752):1543-1551.
• [10]Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307(7):674-684.
• [11]Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31-38.
• [12]Pilz S, Tomaschitz A, Ritz E, Pieber TR: Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009, 6(10):621-630.
• [13]Levin A: Kidneys, hearts, hormones and immunomodulators: integrated understandings. Blood Purif 2006, 24(1):46-50.
• [14]Andrade J, Er L, Ignaszewski A, Levin A: Exploration of association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 2008, 3(6):1800-1806.
• [15]Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86(4):1633-1637.
• [16]Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009, 26(1):19-27.
• [17]Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008, 52(2):249-255.
• [18]Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009, 1(4):Cd008175.
• [19]Andress DL: Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006, 69(1):33-43.
• [20]Gunta SS, Thadhani RI, Mak RH: The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol 2013, 9(6):337-347.
• [21]Sigrist MK, Chiarelli G, Levin A, Romann A, Weber C: Pulse wave velocity measurements are reproducible in multiple trained observers: a short report. Nephron Clin Pract 2010, 116(1):c60-c64.
• [22]Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007, 2(6):1241-1248.
• [23]Meng X, Qie L, Wang Y, Zhong M, Li L: Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Invest Med 2009, 32(6):E238.
• [24]Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S: Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions. Scand J Clin Lab Invest 2006, 66(5):385-394.
• [25]Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S: Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008, 23(2):594-600.
• [26]Xu L, Wan X, Huang Z, Zeng F, Wei G, Fang D, Deng W, Li Y: Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials. PLoS One 2013, 8(4):e61387.
• [27]Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005, 68(6):2823-2828.
• [28]Hathcock JN, Shao A, Vieth R, Heaney R: Risk assessment for vitamin D. Am J Clin Nutr 2007, 85(1):6-18.
• [29]Senn S: Statistical Issues in Drug Development. 1st edition. Chichester: Wiley; 1997.
• [30]de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ: Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013, 24(11):1863-1871.
• [31]Cheng J, Zhang W, Zhang X, Li X, Chen J: Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012, 7(3):391-400.
• [32]Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002, 39(3):486-492.
• [33]Sigrist M, Bungay P, Taal MW, McIntyre CW: Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006, 21(3):707-714. Epub 2005 Nov 2001
• [34]Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003, 63(5):1852-1860.
• [35]Terra SG, Blum RA, Wei GC, Lew RA, Digenio AG, Rajman I, Kazierad DJ: Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials. J Clin Pharmacol 2004, 44(5):457-463.
• [36]Van Breukelen GJ: ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol 2006, 59(9):920-925.
• [37]Senn S: Change from baseline and analysis of covariance revisited. Stat Med 2006, 25(24):4334-4344.
• [38]Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ: Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 2013, 8(7):1143-1149.
• [39]Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19(8):1613-1619.
• [40]Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ, Simon JF, Srinivas TR, Nally JV: Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011, 58(4):536-543.
• [41]Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349(5):446-456.
• [42]Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72(8):1004-1013.
• [43]Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M, Women Health Initiative Investigators: Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115(7):846-854.
• [44]St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008, 51(3):445-454.
• [45]Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
• [46]Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
• [47]Levin A, Lancashire W, Fassett RG: Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. Kidney Int 2013, 83(6):1001-1009.